Yesterday’s Top Performing Small Cap Stock:
Forex International Trading Corp. (OTCBB: FXIT)
Forex International Trading Corp. was a SmallCapVoice.com top performer closing up over 2% on trading volume of 103,900 shares.
Forex International Trading Corp Acquires 50% of Wheatley Asset Management, an NFA Registered Introducing Broker (IB), Forex Firm, and Commodity Trading Adviser (CTA)
Feb. 28, 2011 (Business Wire) — Forex International Trading Corp. (the “Company”) (OTCBB: FXIT), a company, through its affiliates, which is principally engaged in offering a web-based foreign currency trading platform to non-US residents, professionals and retail clients, today announced that it has acquired a 50% equity interest in Wheatley Asset Management (“Wheatley”), an Introducing Broker, Forex firm, and Commodity Trading Adviser, that is registered with the National Futures Association (“NFA”). Wheatley’s Beam FX and Beam Futures divisions specialize in comprehensive Forex and futures education, and offer competitively priced brokerage services and diversified managed Forex and futures programs for portfolio diversification.
Today’s SmallCapVoice.com Hot Stock to Watch:
Image Metrics, Inc. (OTCQB: IMGX)
A New Audio Interview With Image Metrics CEO Robert Gehorsam Is Now at SmallCapVoice.com
AUSTIN, TX — (Marketwire) — 02/28/11 — SmallCapVoice.com, Inc. announced today that a new audio interview with Image Metrics Inc. (PINKSHEETS: IMGX) is now available. The interview can be heard at http://smallcapvoice.com/blog/2-22-11-audio-interview-with-image-metrics-inc-otcqb-imgx
Other Small Cap News
XsunX, Inc. (OTCBB: XSNX)
A New Audio Interview With Tom M. Djokovich, CEO of XsunX, Inc., Is now at SmallCapVoice.com
AUSTIN, TX–(Marketwire – 02/28/11) – SmallCapVoice.com, Inc. announced today that a new audio interview with XsunX, Inc. (http://www.xsunx.com) (OTC.BB:XSNX), a developer of hybrid, thin-film photovoltaic (TFPV) solar cell technologies and manufacturing processes, is now available. The interview can be heard at http://smallcapvoice.com/blog/2-24-11-audio-interview-with-xsunx-inc-otcbb-xsnx
Gammon Gold Inc. (NYSE: GRS)
Gammon 2010 Exploration Adds Proven and Probable Reserves and Measured and Indicated Resources
TORONTO, February 28, 2011 /PRNewswire-FirstCall/ — Gammon Gold Inc. (“Gammon”) (TSX:GAM) and (NYSE:GRS) today reported its updated Reserves and Resources, as at December 31st, 2010 which include the addition of 0.5 million gold equivalent ounces(1) to Proven and Probable Reserves and an increase of 0.2 million gold equivalent ounces(2) to Measured and Indicated Resources.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN)
Rexahn Pharmaceuticals Granted European Patent for New Quinoxalinyl-piperazine Compounds
ROCKVILLE, Md.–(BUSINESS WIRE)– Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.
TechPrecision Corporation (OTCBB: TPCS)
TechPrecision Corporation Receives $1.19 Million Defense Contract Order
Further Diversifies TechPrecision’s Revenue, Adding to its Defense Penetration
WESTMINSTER, Mass., Feb. 28, 2011 /PRNewswire/ — TechPrecision Corporation (OTC Bulletin Board:TPCS) (“TechPrecision”, or “the Company”), a leading manufacturer of large-scale, high-precision machine metal fabrications with customers in the alternative energy, medical, nuclear, defense, aerospace and other commercial industries, today announced that it has received a defense contract order valued at approximately $1.19 million from an existing customer. The order is expected to ship in the first-half of fiscal 2012.
Sangamo Biosciences Inc (NasdaqGM: SGMO)
Sangamo HIV drug shown to boost immune cell counts
Improved CD4 counts in 5 of 6 patients
Feb 28 (Reuters) – A single infusion of Sangamo BioSciences Inc’s (SGMO) experimental HIV treatment improved immune system damage in five of six subjects so far analyzed in the first trial of the therapy in humans.
The small Phase 1 trial involves a drug, known as SB-728-T-902, designed to disrupt a specific gene in order to boost resistance to the fatal and incurable virus.
Trius Therapeutics, Inc. (Nasdaq: TSRX)
Trius Announces Positive Results From Phase 1 Lung Study of Torezolid Phosphate
Second Generation Oxazolidinone Antibiotic Achieves High Exposure in Lung
SAN DIEGO, Feb. 28, 2011 (GLOBE NEWSWIRE) — Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In this study a 200 mg dose of torezolid phosphate was administered orally once-daily for three days to healthy adult volunteers. The trial achieved its primary goal of establishing the steady-state plasma pharmacokinetics and distribution of active drug into epithelial lining fluid (ELF). The same 200 mg once-daily dose of torezolid phosphate is currently being tested in a Phase 3 clinical trial for acute bacterial skin and skin structure infections (ABSSSI).
About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide. Known for its ability to help emerging growth companies build a following among retail and institutional investors, SmallCapVoice.com utilizes its stock newsletter to feature its audio interviews, as well small cap company’s financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our company information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.
The SmallCapVoice.com, Inc. Daily Highlights is an electronic publication, and is for informational purposes only. The Small Cap Voice Daily Highlights covers both client and non client issuers. Non client issuer’s news is listed under other small cap news. SmallCapVoice is an electronic publication providing information on selected public companies. All companies profiled on this website pay cash or restricted stock to SmallCapVoice as consideration for the electronic dissemination of the company’s information and our comments about the company. Section 17(b) of the Securities Act of 1933 requires that SmallCapVoice fully disclose the type consideration (i.e. cash, restricted stock, and restricted stock with registration rights, stock options, stock warrants, or other type consideration) and the specific amount of the consideration our company receives or will receive, directly or indirectly, from an issuer, underwriter, or dealer. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell the securities of the profiled companies. SmallCapVoice is not a registered investment advisor or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. The information contained in our website, e-mail communications and publications are carefully compiled by SmallCapVoice from public sources that we believe to be reliable. SmallCapVoice, however, does not guarantee the accuracy of any information contained in our website, e-mail communications or publications. This material is not a substitute for either one’s own thorough investigation of an investment opportunity or the exercise of good business judgment. SmallCapVoice does not endorse, independently verify, or assert the truthfulness or reliability of any statements or data obtained from third party sources that are published by us about the profiled companies in our website articles, e-mail communications or publications, but we do not publish information that we know is incorrect. Investors should not rely solely on the information contained in our website, e-mail communications or publications when making investment decisions. Instead, investors should use the information provided on the profiled companies as a starting point for conducting additional research that will permit them to form their own opinions regarding the appropriateness of an investment in the profiled company’s securities. SmallCapVoice does not warrant, represent or guaranty that there has been no change in the affairs of the profiled company since the date that information was published on this website, in e-mail communications or in our publications regarding a profiled company or after the date of the profiled company’s press releases or other information disseminated via our website or publications. If you become aware of any change of circumstances related to any website article, e-mail communication or publication, please notify us immediately. See the Contact Us page for the appropriate e-mail address. The information contained in our website, e-mail communications and publications pertains to microcap, small cap and/or other thinly traded securities which by their very nature involve an extremely high degree of risk. An investment in these type of securities could result in the loss of some or all of an investment in the company. In addition, due to the illiquid nature of some of these securities, an investor may find encounter difficulties in liquidating the securities. SmallCapVoice may liquidate the stock consideration it receives at any time it deems it appropriate to do so after the required six-month holding period has run after the completion of the services for which SmallCapVoice was paid in stock. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company’s securities. The following companies have paid, and/or have agreed to pay SmallCapVoice to: distribute the company’s information and reports on this website, to send e-mail communications; to send publications by mail, to post company Internet links on our website, and to compile and/or to distribute reports in an e-mail newsletter.
We encourage our readers to use caution when investing and educate themselves at the web sites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at www.nasd.com. We encourage you to study the SEC’s policies regarding online newsletters at http://www.sec.gov/answers/newsltr.htm. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC’s EDGAR page. The NASD has published information on how to invest carefully at its web site. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our site.
Contact:
Stuart T. Smith CEO
512-267-2430
Podcast: Download (Duration: 15:31 — 14.2MB) | Embed
Based in Aliso Viejo California, XsunX, Inc. is a public reporting company, trading on the Over the Counter Bulletin Board market under the symbol XSNX. Tom M. Djokovich, CEO of XsunX, Inc., called into SmallCapVoice.com and explained how XsunX is developing and has begun to market a new breakthrough manufacturing process to produce low cost, high efficiency thin-film Copper Indium Gallium (di) Selenide (CIGS) thin film solar cells. The company’s patent pending processing technology, called CIGSolar™, focuses on the mass production of individual thin-film CIGS solar cells that can be offered as a non-toxic, high-efficiency and lower-cost alternative to the use of silicon solar cells. XsunX is offering license manufacturing opportunities for its CIGSolar™ technology.